11:31 AM EDT, 10/30/2026 (MT Newswires) -- The UK conditionally approved Ultragenyx Pharmaceutical (UP0.F) unit Ultragenyx Netherlands' oral liquid form of triheptanoin for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders, or LC-FAOD. The British Medicines and Healthcare products Regulatory Agency said Friday that the full marketing authorization for triheptanoin, or Dojolvi, is conditional on further efficacy and safety results from an ongoing pediatric study. LC-FAOD is a group of rare inherited disorders that can put patients at risk of major clinical events due to the body's inability to use long-chain fatty acids as an energy source.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.